LEADERSHIP

Dr. Yuxuan Wu is the co-founder and CEO of YolTech Therapeutics, where he drives the development of next-generation in vivo gene-editing therapies using LNP-mRNA delivery. To date, YolTech has advanced multiple therapeutic programs into clinical stage, with a diversified pipeline spanning genetic, metabolic, cardiovascular diseases.

Prior to YolTech, Dr. Wu developed BRL-101, a CRISPR-based therapy for patients with transfusion-dependent β-thalassemia, which achieved excellent efficacy (Nature Medicine, 2022). From 2015 to 2018, he worked at Harvard Medical School, where he contributed to the development of a CRISPR/Cas9-based editing system for hematopoietic stem cells to treat hemoglobin disorders by reactivating fetal hemoglobin expression (Nature Medicine, 2019, 2020).

Dr. Wu holds a Ph.D. in Biology from Wuhan University.

Prior to Yoltech, Jessie spent six years at Legend Biotech, serving as Vice President of Finance and Investor Relations, and Interim CFO with responsibility of budgetary oversight, achieving profitability targets, long-range financial planning. Throughout her tenure, Jessie was instrumental in executing Legend's capital markets strategy. Her Wall Street acumen helped craft the company's foundational investment thesis.

Jessie brings extensive biotech sector expertise to Yoltech. She previously served as Vice President of Investor Relations and Corporate Finance at Rocket Pharmaceuticals, where she led a $115 million public equity offering, and held biopharma equity research roles at Bank of America Merrill Lynch and Wells Fargo Securities. Her career foundation includes a formative ten-year tenure at JPMorgan spanning both the U.S. and Asian markets.

Jessie earned her MBA from Columbia Business School and a B.S. in Finance and Business Administration from Carnegie Mellon University.